Indoprofen prevents muscle wasting in aged mice through activation of PDK1/AKT pathway

被引:28
|
作者
Kim, Hyebeen [1 ]
Cho, Sung Chun [3 ]
Jeong, Hyeon-Ju [1 ]
Lee, Hye-Young [1 ]
Jeong, Myong-Ho [1 ]
Pyun, Jung-Hoon [1 ]
Ryu, Dongryeol [1 ,2 ]
Kim, MinSeok [4 ]
Lee, Young-Sam [5 ]
Kim, Minseok S. [5 ]
Park, Sang Chul [3 ]
Lee, Yun-Il [3 ]
Kang, Jong-Sun [1 ,2 ]
机构
[1] Sungkyunkwan Univ, Dept Mol Cell Biol, Single Cell Network Res Ctr, Suwon, South Korea
[2] Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea
[3] DGIST, Well Aging Res Ctr, Div Biotechnol, Daegu, South Korea
[4] DGIST, Sch Undergrad Studies, Daegu, South Korea
[5] DGIST, Dept New Biol, Daegu, South Korea
基金
新加坡国家研究基金会;
关键词
Exercise mimetic; Hypertrophic response; Indoprofen; Muscle wasting; Muscle weakness; PDK1; RECEPTOR-GAMMA COACTIVATOR-1-ALPHA; SKELETAL-MUSCLE; DIFFERENTIAL ACTIVATION; FIBER HYPERTROPHY; PROTEIN; EXERCISE; PGC-1-ALPHA; MITOCHONDRIAL; PHOSPHORYLATION; EXPRESSION;
D O I
10.1002/jcsm.12558
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background Muscle wasting, resulting from aging or pathological conditions, leads to reduced quality of life, increased morbidity, and increased mortality. Much research effort has been focused on the development of exercise mimetics to prevent muscle atrophy and weakness. In this study, we identified indoprofen from a screen for peroxisome proliferator-activated receptor gamma coactivator alpha (PGC-1 alpha) inducers and report its potential as a drug for muscle wasting. Methods The effects of indoprofen treatment on dexamethasone-induced atrophy in mice and in 3-phosphoinositide-dependent protein kinase-1 (PDK1)-deleted C2C12 myotubes were evaluated by immunoblotting to determine the expression levels of myosin heavy chain and anabolic-related and oxidative metabolism-related proteins. Young, old, and disuse-induced muscle atrophic mice were administered indoprofen (2 mg/kg body weight) by gavage. Body weight, muscle weight, grip strength, isometric force, and muscle histology were assessed. The expression levels of muscle mass-related and function-related proteins were analysed by immunoblotting or immunostaining. Results In young (3-month-old) and aged (22-month-old) mice, indoprofen treatment activated oxidative metabolism-related enzymes and led to increased muscle mass. Mechanistic analysis using animal models and muscle cells revealed that indoprofen treatment induced the sequential activation of AKT/p70S6 kinase (S6K) and AMP-activated protein kinase (AMPK), which in turn can augment protein synthesis and PGC-1 alpha induction, respectively. Structural prediction analysis identified PDK1 as a target of indoprofen and, indeed, short-term treatment with indoprofen activated the PDK1/AKT/S6K pathway in muscle cells. Consistent with this finding, PDK1 inhibition abrogated indoprofen-induced AKT/S6K activation and hypertrophic response. Conclusions Our findings demonstrate the effects of indoprofen in boosting skeletal muscle mass through the sequential activation of PDK1/AKT/S6K and AMPK/PGC-1 alpha. Taken together, our results suggest that indoprofen represents a potential drug to prevent muscle wasting and weakness related to aging or muscle diseases.
引用
收藏
页码:1070 / 1088
页数:19
相关论文
共 50 条
  • [1] Scaffolding function of PAK in the PDK1–Akt pathway
    Maiko Higuchi
    Keisuke Onishi
    Chikako Kikuchi
    Yukiko Gotoh
    Nature Cell Biology, 2008, 10 : 1356 - 1364
  • [2] Antitumor activity, and suppression of AKT pathway activation by PDK1 inhibitor SNS-391.
    Hansen, Stig K.
    Pathan, Nuzhat
    Sun, Lihong
    Fox, Judith Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays
    Hofler, Alexandra
    Nichols, Tim
    Grant, Stephan
    Lingardo, Laura
    Esposito, Edward A.
    Gridley, Scott
    Murphy, Sean T.
    Kath, John C.
    Cronin, Ciaran N.
    Kraus, Michelle
    Alton, Gordon
    Xie, Zhi
    Sutton, Scott
    Gehring, Mike
    Ermoliefff, Jacques
    ANALYTICAL BIOCHEMISTRY, 2011, 414 (02) : 179 - 186
  • [4] PDK1 neddylation by Smurf1 drives Akt activation
    Manne, Rajesh Kumar
    Kant, Rajni
    Lin, Hui-Kuan
    CELL RESEARCH, 2025, 35 (02) : 95 - 96
  • [5] SD-2102, a novel PDK1 inhibitor, suppresses lung cancer growth by interrupting PDK1/Akt pathway
    Park, Seyong
    Namgung, Hee
    Om, Darlami
    Kang, Juhee
    Jung, Hyunjin
    Shin, Dongyun
    Oh, Seunghyun
    CANCER SCIENCE, 2023, 114 : 1255 - 1255
  • [6] COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization
    Wu, Yi-Hui
    Chang, Tzu-Hao
    Huang, Yu-Fang
    Chen, Chien-Chin
    Chou, Cheng-Yang
    ONCOTARGET, 2015, 6 (27) : 23748 - 23763
  • [7] PDK1/Akt pathway in osteoclast signaling in Paget's disease of bone
    McManus, Stephen
    Laberge, Gino
    Bisson, Martine
    Roux, Sophie
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [8] HIF-1α Regulates Glucocorticoid-Induced Osteoporosis Through PDK1/AKT/mTOR Signaling Pathway
    Xu, Wen-Ning
    Zheng, Huo-Liang
    Yang, Run-Ze
    Jiang, Lei-Sheng
    Jiang, Sheng-Dan
    FRONTIERS IN ENDOCRINOLOGY, 2020, 10
  • [9] Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase
    Ding, Zhiyong
    Liang, Jiyong
    Li, Jin
    Lu, Yiling
    Ariyaratna, Vathsala
    Lu, Zhimin
    Davies, Michael A.
    Westwick, John K.
    Mills, Gordon B.
    PLOS ONE, 2010, 5 (03):
  • [10] Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells
    Sawamukai, Norifumi
    Saito, Kazuyoshi
    Yamaoka, Kunihiro
    Nakayamada, Shingo
    Ra, Chisei
    Tanaka, Yoshiya
    JOURNAL OF IMMUNOLOGY, 2007, 179 (10): : 6479 - 6484